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ABSTRACT
Solid dispersion (SD) has been a major advanced technology in overcoming dissolution and bioavailability problem of poorly soluble compounds. 
Formulation of SD in water-soluble carrier has becoming more researched over the past four decades for solubility and relative bioavailability 
enhancement. By reduction of the size of the drug particle to the minimum level which will enhance drug wettability and ultimately bioavailability 
will be definitely improved. This review article elaborates recent advanced technology and characterization of SDs and also discusses the problems 
and their solution for the development of better formulations.
Keywords: Solid dispersion, Poorly water-soluble drug, Problems and solution, Preparation and characterization, Future perspective and strategies.
INTRODUCTION
The progress in the treatment of diseases has been evident with an 
upsurge in development of new drugs. An estimated 40% of these 
drugs are poorly water soluble especially those belonging to the 
biopharmaceutics classification system Class II and IV. Although most 
of the drugs have encouraging experimental data obtained in vitro, the 
in vivo results have been disappointing [1]. The attributes include:
1. Poor absorption, rapid degradation, and lamination (peptides and 
protein) resulting in insufficient concentration
2. Drug distribution to other tissues with high drug toxicities 
(anticancer drugs)
3. Poor solubility of drugs
4. Fluctuations in plasma levels due to unpredictable bioavailability
5. High interpatient variability.
The enhancement of oral bioavailability of such poorly water-soluble 
drugs is a biggest challenge in the pharmaceutical development [2].
Many solubilization techniques have been described that either change 
the nature of the solvent environment (cosolvent systems, emulsions, 
and micellization) or the chemical identity of the dissolved solute 
(salt formation, complexation, and prodrugs). Particle size reduction 
by micronization or nanonization can enhance the dissolution 
rate; however, the apparent solubility remains unaltered [3]. Solid 
dispersions (SDs) contribute by slowing devitrification, enhancing 
wettability and modulating the properties of the solvent [4]. The 
development of SDs is most practically viable approaches to enhance 
the bioavailability of poorly soluble drugs due to high drug loading 
(e.g. 250 mg per tablet in Incivek) and/or containing drugs with high 
susceptibility to crystallize indicating high melting point (e.g. 291°C of 
ivacaftor in kalydeco) Table 1.
CLASSIFICATION OF SD
Based on the physical state of the carrier the SD is categorized as 
crystalline SD and amorphous SD. It is classified into a first generation, 
second generation, third generation, and fourth generation.
First generation
In the first generation, crystalline carriers were generally used in SDs. 
Urea and sugars are considered as a first crystalline carrier in the 
preparation of SD. Urea was used as a first crystalline carrier to form 
eutectic mixture with sulfathiazole (Sekiguchi and Obi) [5]. Okonogia 
et al. [6] had tried to enhance the dissolution of ofloxacin by using 
carrier, urea, and mannitol by SD technique. He had observed that the 
dissolution rate of ofloxacin was manifold in urea than mannitol based 
SDs due to the reduction of crystallinity of ofloxacin.
Second generation
The second generation contains amorphous carrier instead of 
crystalline one. They have the ability to produce amorphous SD 
in which drug and carrier are uniformly miscible and soluble 
to originate a homogenous molecular interaction [7]. Povidone, 
polyethylene glycol (EG) polymethacrylate is fully synthetic polymer 
and natural product based polymer include cellulose derivative, 
such as hydroxylpropyl methylcellulose (HPMC), ethyl cellulose or 
hydroxypropylcellulose (HPC), or starch derivatives like cyclodextrin. 
Kohri et al. [8] had described that the dissolution of all formulation 
of albendazole has been improved using HPMC and hydroxypropyl 
methylcellulose phthalate (HPMCP). Table 2 summarizes that 
nowadays HPMC and HPMCP have been successfully applied in many 
marketed SD product.
Third generation
In the third generation, new technology has been adopted to overcome 
the drawbacks such as precipitation and recrystallization using self-
emulsifier and surface active agent. The utilization of these carriers 
not only improves the dissolution profile but also the physical and 
chemical stability of the drug. The surfactant used in SD is poloxamer, 
gelucine44/14 [10], solupus [9], inutec sp1 [13], compritol 888 
ATO [11] sodium lauryl sulfate (SLS), d-alpha tocopheryl PEG 1000 
succinate (TPGS-1000) [14], polyoxyethylene hydrogenated castor 
oil, Tween 80, and sucrose laurate is used in SD. Ali et al. [12] had 
investigated that both ibuprofen and ketoprofen dissolution has been 
enhanced using poloxamer 407 and 188. An inulin derivative inutec 
sp1 which was discovered as a novel carrier in the research of Van 
den Mooter [13] de Waard et al. [15] observed that the dissolution of 
sucrose glass based SD by taking SLS was strongly increased compared 
to a standard tablet.
Fourth generation
In the fourth generation, the aim of introducing SD is for solubility 
enhancement and extended release in a controlled manner. In this 
system, the poorly water-soluble drug is dispersed in either water-
soluble carrier or water-insoluble carrier [16]. The water-insoluble 
carrier used in SD is ethyl cellulose, eudragit RS, eudragit RL, HPC, 
polyethylene oxide (PEO), and carboxyvinyl polymer (carbomer). 
Cui et al. [17] had formulated sustained release nitrendipine (NTR) 
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microsphere using HPMC - 55 and Aerosil for improving dissolution of 
NTR while Eudragit RSPO and ethyl cellulose were used as the retarding 
agent to control the release of the drug.
ADVANTAGES OF SD
In contrast to other technique, such as salt formation, particle size 
reduction, and solubilization for enhancement of bioavailability. SD 
flash many more valuable advantages to become one of the most 
promising strategies:
1. SD technique can reduce the size of the particle for enhancement of 
bioavailability.
2. Due to supersaturation, the size of the precipitated particle cannot 
be affected. So that the dissolution rate is always higher [18].
3. It will improve the drug wettability by increasing the water 
absorption capacity.
4. It will reduce agglomeration by incorporating surfactant and emulsifier.
5. The crystalline structure of the drug is reduced to amorphous form.
6. It improves the porosity by rapid evaporation of solvent.
7. It improves dissolvability in water of a poorly water-soluble drug in 
pharmaceutical.
8. By incorporating polymer and other excipients, it will improve mask 
of the taste of the drug substance.
9. To promote and develop release of sustained release dosage form.
10. It stabilizes the unstable product.
DISADVANTAGES OF SD
During storage and processing (temperature and humidity stress) the 
amorphous state may undergo recrystallization due to the presence of 
moisture in amorphous which effect on storage stability of amorphous 
particle [19].
The physical state, i.e., its crystallinity and dissolution characteristic of 
a drug must be affected due to phase separation, crystal growth, or a 
change from metastable form to stable form [20].
During formulation sometimes it may form hard lump which is very 
difficult to break on a large scale. In melting method, drug and carrier 
produce thermal instability. Solvent residue is present after solvent 
evaporation method.
APPROACHES TO OVERCOME THE COMMON OBJECTION ARISE 
FROM SD
1. To prevent crystallization and phase separation, the polymer must 
be miscible with drug. If the polymers have high glass transition 
temperature (Tg) compared to API, the molecular mobility is 
decreased, and the miscibility is increased [21].
2. Vasanthavada et al. [22] had investigated that the phase separation 
rate proportional to the drug-polymer interaction and the drug 
content of the dispersion by taking griseofulvin-polyvinylpyrrolidone 
(PVP) and ibuprofen-PVP SDs.
3. Surfactants and emulsifier also reduce crystallinity by improving 
miscibility of drug and polymer.
4. Surface active agent can also increase the solubility of drug and 
carrier in an organic solvent in the solvent method.
5. Surface active agents also increase drug wettability and inhibit the 
precipitation process by adsorbing the surface of drug particle and 
forming micelles encapsulating drugs.
6. Mura et al. [23] explained the effect of non-ionic surfactant 
including SLC, dioctyl sulfosuccinate on the ketoprofen–PEG. 
They had shown that the dissolution rate of ketoprofen-PEG is 
improved.
7. There are many techniques developed to increase solidification 
process (cooling and solvent removal) such as ultrarapid freezing 
to prevent recrystallization of drugs.
PREPARATION TECHNIQUES
SD is a very highly efficient technique whose methods have been 
developed from various years. Nowadays some novel techniques have 
been introduced for preparation of SD. SD is prepared by three methods 
such as melting method, solvent evaporation method, and solvent 
melting method.
MELTING TECHNIQUE
The melting method involves the preparation of physical mixture by 
melting drug into the water-soluble carrier at a temperature above 
eutectic point. Then, the melted liquid is going to be solidified, crushed, 
pulverized, and sieved [24]. Kolašinac et al. [25] had investigated that 
solubility and dissolution rate of desloratadine have been increased 
by using poloxamer p. 188 and poloxamer p. 407 by applying melting 
method at low temperature (70°C). There are several methods which 
Table 1: FDA approved medicines that use solid dispersion technologies
Product Drug Polymer Dose (mg) API Tm(°C) Dispersion method
Novir Ritonavir PVP-VA64 100 122 Hot melt extrusion
Kaletra Lopinavir/ritonavir PVP-VA64 200/50 125/122 Hot melt extrusion
Incivek Telaprevir HPMC-AS 250 246 Spray drying
Nivadil Nilvadipine HPMC 4 173 Solvent evaporation method
Zelboraf Vemurafenib HPMC-AS 210 272 Co-precipitation
Kalydeco Ivacaftor HPMC-AS 150 291 Spray drying
Intelence Etravirine HPMC 100 265 Spray drying
Onmel ITZ HPMC 200 166 Hot melt extrusion
Prograf Tacrolimus HPMC 5 128 Spray drying
Zortress Everolimus HPMC 0.75 115 Spray drying
ITZ: Itraconazole, FDA: Food and drug administration, HPMC: Hydroxypropyl methylcellulose, AS: Antisolvent
Table 2: Successfully prepared marketed solid dispersion 
product using HPMC and HPMCP
Product Drug Type of carrier Dosage 
form
Intelence Etravirine HPMC Tablet
Zelboraf Vemurafenib HPMC AS Tablet
Incivek Telaprevir HPMCAS-M Tablet
Crestor Rosuvastatin HPMC Tablet
Nivadil Nilvadipine HPMC Tablet
Rezulin Troglitazone HPMC Tablet
Prograf Tacrolimus HPMC Capsule
Sporanox ITZ HPMC Capsule
Certican Everolimus HPMC Tablet
Isoptin SR-E Verapamil HPC/HPMC Tablet
Cesamet Nabilone PVP Tablet
Gris-PEG Griseofulvin PEG Tablet
Afeditab CR Nifedipine Poloxamer/PVP Tablet
Fenoglide Fenofibrate PEG Tablet
Kaletra Lopinavir/Ritonavir PVPVA Tablet
HPMC: Hydroxypropyl methylcellulose, HPMCP: Hydroxypropyl 
methylcellulose phthalate, AS: Antisolvent, HPC: Hydroxypropylcellulose, 
PVP: Polyvinylpyrrolidone vinyl acetate, PEG: Polyethylene glycol, 
ITZ: Itraconazole
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are developed to overcome its limitation. They are hot melt extrusion 
method, MeltrexTM and melt agglomeration method.
Hot melt extrusion method
It is a complete system in which both the drug and carrier are 
simultaneously melted, homogenized and extruded in the form of 
tablets, rods, pellets, and blended with different intention [26]. Ye 
et al. [27] had described a Novel Method of Continuously Preparing 
Nanocrystal SDs of poorly soluble drug Efavirenz. They had combined 
high pressure homogenization and hot melt extrusion (HME) which 
was proved to be a promising novel method for the production of 
nanocrystals SD. Desai et al. [28] had formulated solid solution of 
Ritonavir for enhancement of solubility by hot melt extrusion method. 
They had shown that the solubility of Ritonavir was increased by 
formulating a solid solution with a novel polymer Soluplus due to its 
low hygroscopicity and low glass transition temperature which made it 
suitable for hot melt extrusion.
MeltrexTM
It is an advanced technology which is based on the principle of hot 
extrusion technology. This process is applied those drugs which are 
sensitive to oxidation and hydrolysis because oxygen and moisture can 
be eliminated during the process. In this system, the two independent 
hoppers and a special twin screw extruder allow conveying the 
extruded mass continuously throughout the extrusion channel [29]. 
The temperature of all barrels may be controlled from low temperature 
(30°C) to high temperature (250°C).
Melt agglomeration
It is a feasible method in which the carrier acts as a meltable binder. 
Melt agglomeration is processed in three ways in a rotary processor. 
It is processed by adding the molten carrier containing the drug to 
the heated excipients [30] or adding the molten carrier to a heated 
mixture of drug and excipients or heating a mixture of drug, carrier, and 
excipients to a temperature within or above the melting range of the 
carrier. Helle et al. [31] had produced SD of a poorly water-soluble drug, 
Lu–X by melt agglomeration of Lactose monohydrate and Lu–X with 
Rylo MG12, Gelucire 50/13, PEG 3000, or poloxamer 188. The result 
showed that the agglomerates containing SD had improved dissolution 
rates compared to physical mixtures and pure drug.
SOLVENT EVAPORATION TECHNIQUE
In this method, the drug and carrier are solubilized in an organic 
solvent. The solvent used in this method is ethanol, methanol, acetone, 
ethyl acetate, and methylene chloride [32]. Some surfactants are used 
such as Tween 80 and SLS which increases the solubility of drug and 
carrier in solvents. For fast removal of solvent from solution, some 
of the methods have been developed such as centrifugal spinning 
method, electrostatic spinning method, supercritical antisolvent (SC-
AS) method, SC fluid technology, spray freeze-drying (SFD), ultra rapid 
freezing, freeze-drying, spray drying, coprecipitation method, and fluid 
bed coating. In Table 3, Different solvent evaporation technique are 
used in recent article for improvement of bioavailability of different 
poorly soluble drug..
Centrifugal spinning technique
Centrifugal spinning method is an alternative technique to fabricate 
nanofibers from various material and high cost [33]. In this method, 
the spinning fluid is lodged in rotating spinning head. When the speed 
of rotation reached a critical value, the centrifugal force reduces the 
surface tension of spinning fluid. So that a liquid jet is ejected from 
the `nozzle tip of the spinning head. Then, the liquid jet undergoes 
stretching process and is deposited on the collector to produce solidified 
nanofibers. It is simple and produces rapid fabrication of nanofibers for 
various applications.
Jiang et al. [34] had used a centrifugal spinning method instead of 
electrospinning method due to difficulty in high scale-up of carbon 
nanofibers. They had prepared tin-containing carbon nanofibers from 
tin chloride polyacrylonitrile precursor solutions with an excellent 
reversible capacity of 607 mAh g−1and high specific capacity of 430 
mAh g−1. Hence, they had investigated that this method shown great 
potential in large-scale nanofibers production.
Electrostatic spinning technique
Electrostatic spinning method is a finest technique and considered a 
combination of SD technology and nanotechnology. In this process, 
when electrical forces overcome the surface tension of the drug/
polymer solution at the air interface, fibers of submicron diameters 
are formed and collected on a screen to give a nonwoven fabric, or they 
can be collected on a spinning mandrel. The fiber diameters depend 
on surface tension, dielectric constant, feeding rate, and electric field 
strength. Paaver et al. [35] had used electrospinning technique, for 
preparing HPMC based polymeric nanofibers of a poorly water-soluble 
drug Piroxicam (PRX). They had concluded that electrospinning can 
be used to fabricate supersaturating controlled release-SD (CR-SD) 
nanofibers of PRX and HPMC and to stabilize the amorphous state of 
PRX.
SC-AS method
The SC ant solvent technique is a very impressionable technique 
for micronization of drug product. In this method SC-CO2 is used as 
solubilizing solvent or antisolvent. The SC-CO2 is quickly mixed up with 
an organic solvent which causes precipitation of solutes by ant solvent 
effect [36]. Then SC-CO2 efficiently extracts organic solution to obtain 
completely solvent-free products. This method can also be used to 
encapsulate or coprecipitate different active compounds and carrier 
materials, thus producing micro composites and microcapsules.
SC fluid technology
Supercritical fluid technology exhibits magnificent opportunities to 
improve the drug delivery sector. This method uses CO2 as solvent whose 
temperature and processor are above the critical point. Under lower 
pressure, the rapid nucleation of the dissolved drug and carrier in CO2 
leads to the formation of SD particle with a desirable size distribution 
in a very short time. Gang et al. [37] had applied supercritical fluid 
technology for improving the dissolution and bioavailability of silymarin 
using a carrier, polyvinylpyrrolidone K17 and supercritical CO2. The 
result was shown that the bioavailability of silymarin was increased 
using SC fluids. The ability to rapidly vary the solvent (or antisolvent) 
strength and, thereby, the rate of supersaturation and nucleation of 
dissolved compounds is exploited as an alternative technology for 
particle formation under various names that are essentially based on 
three key process concepts:
1. Precipitation from SC solutions-rapid expansion of SC solution 
(RESS);
2. Precipitation from saturated solutions using SCF as an antisolvent-
gas antisolvent, precipitation with compressed antisolvent, SC 
antisolvent, aerosol solvent extraction system (ASES), and solution 
enhanced dispersion by SC fluids process; and
3. Precipitation from gas-saturated solutions - particles from gas-
saturated solutions (PGSS).
The applicability of RESS for preparation of SDs is limited by the very 
low or negligible solubility of most drugs and polymers in the commonly 
used SC CO2. In the PGSS process, the rapid cooling and expansion of 
CO2 produces fine particles with a narrow particle size distribution and, 
thereby, avoids the comminution step.
SFD
SFD is one of the most efficient technique that originates stable and 
unique powder product. This method increases freezing temperature 
and reduces the particle size of the drug particle without using frictional 
and mechanical forces. Shaofeng et al. [38] had used the spray-freeze-
drying technique by preparing HPC based microparticles (MSM) loaded 
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poorly soluble drug nanocrystals. They had concluded that the spray-
freeze-dried composite particles with HPC ratio of 1:2, 1:1, and 2:1 
possessed excellent redispersibility and produced cage-like MSM.
Ultra rapid freezing
In this technique, the frozen particles are collected by applying drug-
polymer solution to a solid cryogenic substrate. Then, the solvent is 
removed by lyophilization. Badens et al. [39] compared SFD with SC ant 
solvent method on Oxeglitazar. They investigated that SFD shown lower 
crystallinity and higher dissolution rate.
Freeze-drying
This process involves immersing the drug carrier solution in liquid 
nitrogen until the solution at frozen state. Then, the frozen solution is 
then lyophilized. The best advantage is that it reduces the risk of phase 
separation and disadvantage is that the most of the organic solvent do 
not stay frozen due to low freezing temperature. Wei-Juan et al. [40] 
had improved the dissolution rate and oral bioavailability of Valsartan 
using PEG 6000 (PEG 6000) and HPMC 100KV as hydrophilic polymers, 
without using any organic solvents. It was shown that the Valsartan SDs 
exhibited significantly higher values of AUC0–24h and Cmax in comparison 
with the pure drug.
Spray drying
It is one of the most efficient technologies for manufacturing of SD. In 
this technique, the drug carrier solution is passed through the nozzle 
and atomized into very fine droplets with the increased surface area. 
These droplets are going for evaporation process and produce SDs 
commercially available spray dryer such as incivek and intelence which 
is utilized for production of SDs. Kaur et al. [41] had presented the 
formulation of SD containing polypeptide-k to enhance its aqueous 
solubility using trehalose and Tween-80 they had concluded that the 
optimized batch of formulation had exhibited higher solubility in water 
as well as various aqueous buffers as compared to pure polypeptide-k. 
Ramesh et al. [42] had enhanced the dissolution rate of Etravirine 
by converting it from crystalline to amorphous form by spray drying 
method. They had used various polymers such as Solupus and Povidone 
which covert it into highly soluble amorphous form. They had suggested 
that spray drying method is an efficacious method which enhances the 
solubility as well as the release rate of Etravirine.
Fluid bed coating
In this method, the solution mixture of drug and carrier is sprayed 
through a nozzle onto the surface of nonpareil pellet in a fluid bed 
coating. Li et al. [43] had prepared resveratrol (RES) mesoporous 
silica MSM SD by fluid bed coating method. They had found that RES 
mesoporous silica MSM shown higher drug loading and more complete 
dissolution in comparison with solvent equilibrium method.
MELTING SOLVENT METHOD
It is a combinational technique of the melting method and solvent 
method. In this combo technique, first, drugs are dissolved in suitable 
solvent and mixed with a molten carrier. Then remove the solvent and 
solidified to form SD. The benefit of this technique is that it protects 
the drug from thermal degradation by lowering the temperature and 
mixing time.
Surface-active carriers
A surface-active carrier may be preferable in almost all cases for the SD 
of poorly water-soluble drugs. The surface-active and self-emulsifying 
carriers for SD of poorly water-soluble drugs have been of great 
interest in recent years. Two of the important surface-active carriers 
are Gelucire 44/14 and Vitamin E R-alpha-1000 succinate TPGS. 
Gelucire 44/14 (Gattefosse´ Corp, Gennevilliers, France) has commonly 
been used in SD for the bioavailability enhancement of drugs [44-46]. 
Gelucire 44/14 is a mixture of glycerol and PEG 1500 esters of long-
chain fatty acids and is official in the European Pharmacopoeia as 
lauroyl macrogolglycerides; the suffixes 44 and 14 in its name refer, 
respectively, to its melting point and hydrophilic-lipophilic balance 
(HLB) value. Vitamin E TPGS national formulary Eastman, Kingsport, 
TN) is prepared by the esterification of the acid group of d-R-tocopheryl 
acid succinate by PEG 1000. The material has an HLB value of 13 and is 
miscible with water in all parts. Its melting point, however, is relatively 
low (38°C), and it may require mixing with other carriers to increase 
melting temperatures of formulations.
CHARACTERIZATION OF PHYSICOCHEMICAL PROPERTIES:
Many instrumental and analytical techniques are used to characterize 
the physicochemical properties of SD. They are differential scanning 
calorimetry (DSC), Modulated DSC (MDSC), powder X-ray diffraction 
(PXRD), and other technique such as Fourier transformed infrared 
spectroscopy (FTIR), attenuated total reflection (ATR)-FTIR spectroscopy, 
Solid state nuclear magnetic resonance, and thermal gravimetry analysis 
(TGA).
DSC
It is a thermoanalytical technique which is used to measure the 
temperature and heat flow associated with a transition in material as a 
function of time and temperature [47]. Berndl et al. [48] had investigated 
that the endotherm of SD of Itraconazole is which means that it assumes 
lower endotherm property which led to bioavailability improved.
MODULATED MDSC
Modulated DSC is a novel thermal technique which provides an exciting 
new way to significantly increase the basic understanding of material 
Table 3: Recent article on preparation of solid dispersion for poorly soluble drug using different solid dispersion technique
Drug Carrier SD technique Reference
Silymarin Polyvinylpyrrolidone K17 SC fluid technology Gang et al. [37]
Polypeptide-K Trehalose, tween-80 Spray drying Kaur et al. [41]
valsartan PEG 6000
HPMC 100KV
Freeze-drying Wei-Juan et al. [40]
Curcumin Eudragit® EPO Solvent evaporation method Li et al. [59].
Tadalafil PVP/VA 630, Mallic acid or meglumine and Aerosil 200 Solvent evaporation method Choi et al. [54]
Poorly soluble drug HPC Spray freeze drying Shaofeng et al. [38]
Pseudomonas podoviridae 
phage PEV2
Trehalose, mannitol, l-leucine SFD and spray drying Leung et al. [63]
Paracetamol Ethyl cellulose, mesoporous silica Fluid bed system Hacene et al. [60]
ITZ, OLZ PRX Sucrose Centrifugal spinning 
method
Marano et al. [61]
HPMC: Hydroxypropyl methylcellulose, HPMCP: Hydroxypropyl methylcellulose phthalate, AS: Antisolvent, PVP: Polyvinylpyrrolidone vinyl acetate, 
PEG: Polyethylene glycol, HPC: Hydroxypropylcellulose, PRX: Piroxicam, SC: Supercritical, SFD: Spray freeze drying, PVPVA: Polyvinylpyrrolidone vinyl acetate, 
PEG: Polyethylene glycol, OLZ: Olanzapine, ITZ: Itraconazole, SD: Solid dispersion
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properties. Guinot and Lavillar [49] had described that this method was 
successfully used to detect and quantify amorphous phase transition. It 
has significant benefits over conventional DSC. These include:-
a. More accurate measurement of crystallinity of semi-crystalline 
polymer.
b. Thermal conductivity is measured.
c. Determination of heat flow and heat capacity in a single experiment.
d. High resolution is detected without compromising sensitivity.
e. Weak transition can be detected as compared to standard DSC.
PXRD
It is used to indicate phase identification, crystallinity, phase transition, 
and determination of crystal structure of a drug in SD. It provides 
diffraction peaks that indicate crystalline compound with characteristic 
fingerprint region. The drug crystallinity can be individually identified 
from the carrier crystallinity and differentiate the amorphous and 
crystalline state of the drug in SD [18].
SPECTROSCOPY (FTIR)
It is a technique which is used to investigate the physical and chemical 
interaction between drug and carrier. FTIR identified hydrogen bonding 
between drug and carrier which is more important to describe its 
physical state and stability of the drug. Miyazaki et al. [50] investigated 
the crystalline state of NTR enantiomer in the presence of PVP, HPMCP, 
and HPMC. FTIR result was shown that hydrogen bonding between PVP 
and NTR crystal in PVP based is lowered as compared to HPMC and 
HPMCP based SD.
ATR-FTIR
Nowadays IR measurement are performed in ATR mode. It is a 
simple and novel technique of sampling in which all types of samples 
(e.g. solids, liquid, powders, pastes, pellets, slurries, and fibers) are 
placed undiluted on the ATR crystal. The measurement is typically 
performed within a few seconds. The advantages of ATR-FTIR 
technique on conventional FTIR technique is fast sampling with no 
preparation, excellent sample to sample reproducibility, and minimal 
operator induced variation. Hifumi et al. [51] had presented the novel 
application of ATR-FTIR spectroscopic imaging to study the drying 
process and dissolution behavior of polymer-based film of ibuprofen. 
Fig. 1 shows analysis of the purified membrane protein by ATR-FTIR 
method.
THERMAL GRAVIMETRY ANALYSIS (TGA)
It is a thermal analysis technique which provides information about the 
stability of the drugs and carrier as well as their physical and chemical 
process involved in the preparation of SD. Frizon et al. [52] investigated 
the thermal stability of Loratadine using TGA method. The result 
shown that Loratadine has been stable up to 203°C and has no chemical 
interaction between drug and polymer.
SOLID STATE NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
It is a technique which provides detailed structural information about 
SD of pharmaceutical small molecules. It is a characterization tool for 
elucidating the structure of amorphous SD. It is used for identification, 
characterization and quantification of various solid forms of drug 
candidates (polymorphs, hydrates, solvate, salt, cocrystal, amorphous, 
mesomorphous, etc.) during drug development [53].
Hence, physicochemical evaluation is essential for SD to investigate 
the pharmaceutical applicability and thoroughly understand the 
pharmaceutical mechanism of drug dissolution enhancement and 
physicochemical stability.
FUTURE PERSPECTIVE AND STRATEGIES
Due to the existence of most of the poorly water-soluble drug, the SD 
has been grown with much interest toward improving dissolution 
and bioavailability. Hence, many novel carrier, additives, and new 
preparation technique are applying for this purpose.
In recent year some novel carrier such as Surplus® inutec sp1 or 
Kollicoat® IR in SD for improving and expanding the SD. Choi et 
al. [54] had applied solvent evaporation method for improving the 
solubility of Tadalafil (TDF), using hydrophilic carriers (PVP/VA S-630) 
and assistants (malic acid or meglumine). It was concluded that the 
optimal TDF-SD formulation had exhibited a greater dissolution rate 
(89.1±3.9%) than TDF alone. Nowadays many novel excipients are 
also used for improving solubility of API. These excipients include 
super disintegrants, novel surfactants, and pH modifier. Wang et al. 
[55] had prepared Ginkgo biloba extract SD (GBE-SD) through HME 
using a carrier such as Kollidon® VA64/Kolliphor® RH40 (85:15) 
spray dried powder. The result was shown that the dissolution rate 
and oral bioavailability of GBE were enhanced. Srinarong et al. [56] 
utilized super disintegrant in SD to prepare tablet. They explained that 
dissolution rate is enhanced by preventing recrystallization during the 
dissolution process.
In the fourth generation, centrifugal spinning method is a novel method 
of CR-SD. It is a highly efficient technique for fabricating nanofibers 
for the preparation of SD. Marano et al. [57] developed microfibrous 
to nanofibrous SD of poorly water-soluble drug in sucrose using 
temperature controlled centrifugal spinning method. This study 
was demonstrated that nanofibers based dispersion may possess 
characteristics that are favorable for the enhanced dissolution and oral 
absorption of drugs.
Many advanced characterization has been developed such as high-
performance DSC, project rapid heat/cool, and chip calorimetry 
which are applied in SD area. Yu et al. [58] investigated the structure 
and dissolution properties of a SD containing Lansoprazole and PVP. 
Hence, there are more and more strategies will be needed to overcome 
remaining problems of SD in future.
CONCLUSION
From the above study, SD is one of the efficient technologies for 
overcoming many problems relating to bioavailability of poorly 
soluble drug. Still, there has some problem which will be short out by 
applying novel and current approach. This review focuses on current 
effort to short out bioavailability problem and explains various new 
technologies involved for development of SD. The investigation of 
research will be more on physicochemical properties, interaction of 
drugs and carrier and characterization technique which will help to 
elucidate the structure and dissolution properties of SD.
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